bit.bio discovery combines single cell functional genomics with best-in-class cellular models to decipher complex cellular pathways and gain a better understanding of disease development. This next-generation CRISPR screening platform will help to understand the role of gene networks at unprecedented scale and resolution to discover and validate novel drug targets.
R&D:bit.bio discovery will capitalize on bit.bio’ s unique ability to reprogram cells, which has so far yielded glutaminergic neurons and skeletal myocytes. Additional cell types are expected to become available over the course of the this year. Cells are produced at unprecedented homogeneity and differentiation is much more reproducible than conventional protocols.
Services:By creating and utilising physiological relevant, pure and consistent human cell types, with matched disease models, bit.bio discovery offers customers an ever-expanding opportunity to perform CRISPR screens for the discovery and validation of novel drug targets or to elucidate the mechanism of action of drugs.